PURPOSE: To evaluate the effectiveness of pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration. METHODS: This retrospective review included patients who received pegaptanib combined with 165 microg of moxifloxacin every 6 weeks. Ophthalmic examination was performed, and adverse events were recorded at each visit; additional assessments (e.g., optical coherence tomography) were performed when indicated. RESULTS: Eighty eyes of 65 patients were identified; the median length of follow-up was 13.2 months (range, 10-16 months), and eyes received an average of 6 injections (range, 4-9 months). Seventy eyes of 80 patients have been followed for >or=1 year; 80% (65/70) had stable or improved vision, and 97% (68/70) lost <15 letters of vision. CONCLUSION: Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration.
PURPOSE: To evaluate the effectiveness of pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration. METHODS: This retrospective review included patients who received pegaptanib combined with 165 microg of moxifloxacin every 6 weeks. Ophthalmic examination was performed, and adverse events were recorded at each visit; additional assessments (e.g., optical coherence tomography) were performed when indicated. RESULTS: Eighty eyes of 65 patients were identified; the median length of follow-up was 13.2 months (range, 10-16 months), and eyes received an average of 6 injections (range, 4-9 months). Seventy eyes of 80 patients have been followed for >or=1 year; 80% (65/70) had stable or improved vision, and 97% (68/70) lost <15 letters of vision. CONCLUSION:Pegaptanib combined with intravitreal injection of moxifloxacin appears to be effective treatment of wet macular degeneration.
Authors: David M Hinkle; Nicole A Kruh-Garcia; Jonathan N Kruh; Carolyn Broccardo; Priyanka Doctor; C Stephen Foster Journal: Open Ophthalmol J Date: 2017-06-12